Table 4 Maspin expression in lung cancer
From: Role of maspin in cancer
Authors | Years | N. patients | Maspin expression | Clinical features/prognosis/predictive factors |
|---|---|---|---|---|
Bircan et al. | 2010 | 28 (squamous cell lung cancer) | 89.3% positive maspin | |
18 (lung adenocarcinoma) | 77.8% positive maspin | |||
17 (small cell lung cancer) | 52.9% positive maspin | |||
Lonardo et al. | 2005 | 46 (squamous cell lung cancer) | 100% positive maspin | Positive maspin = almost exclusively nuclear position |
77 (lung adenocarcinoma) | 93,5% positive maspin | Positive nuclear maspin in squamous cell lung cancer = low grade, low proliferative rate, absence of invasion, negative p53 vs nuclear-cytoplasmic position. | ||
Frey et al. 2009 | 2009 | 80 (lung adenocarcinoma) | 93.7% positive maspin | |
62.6% positive nucleus | Positive nuclear maspin = 36.6% proliferative rate, Stage I OS: 87.7 ± 6.9 months, 42.5% moderate and poor differantation, 25,5% p53+, 4.2% high VEGF | |||
37.3% positive cytoplasm - nucleus | Positive cytoplasmic maspin = 56.9%proliferative rate, Stage I OS: 58.7 ± 6.5 months, 71.4% moderate and poor differantation,53.5% p53+, 39.2% high VEGF | |||
Woenckhaus et al. | 2007 | 487 (tissue microarrays) | 72.3% positive maspin | |
65.3% positive nucleus | Positive nuclear maspin = 63.9% squamous cancer, 16.9% | |||
37.8% positive cytoplasm | Positive cytoplasmic maspin = 78.2% squamous cancer, 6.8% adenocarcinoma adenocarcinoma | |||
Hirai et al. | 2005 | 112 (non-small cell lung cancer) | 55.3%positive maspin | Positive maspin = 77.8% positive cytoplasm Stage III and 36.2% positive cytoplasm Stage I |
44.7% negative maspin | ||||
Berardi et al. | 2010 | 439 (non-small cell lung cancer) | 85.6% positive maspin | Positive maspin = longer OS |
22.8% positive nucleus | Positive nuclear maspin = independent prognostic factor | |||
44% positive cytoplasm | Positive cytoplasmic maspin = especially smokers, lower OS than nuclear position | |||
14.4% negative maspin | Negative maspin = Lower OS | |||
Wu et al. | 2012 | 160 (non-small cell lung cancer) | 48.1% positive maspin | Positive maspin = lower vasculogenic mimicry and microvessel density, longer OS, low Stage, low grade, low lymphnode metastasis |
51.9% negative maspin | Negative maspin = higher vasculogenic mimicry and microvessel density, lower OS, high Stage, high grade, lymphnode metastasis | |||
20 (normal tissue) | 100% positive maspin | |||
Nakagawa et al. | 2006 | 210(non-small cell lung cancer) | 73.7% positive maspin in squamous cancer | Positive maspin = 70.1% 5-years OS |
26.3%negative maspin in squamous cancer | Negative maspin = 41.5% 5-years OS | |||
Katakura et al. | 2006 | 55 (non-small cell lung cancer) | Not found | Positive maspin = 67.7% 5-years OS |
Negative maspin = 41.4% 5-years OS | ||||
Takanami et al. | 2008 | 181 (non-small cell lung cancer) | 40.8%positive maspin | |
65.7% positive maspin in squamous cancer | Positive maspin in squamous cell lung cancer = 52.2% 5-years OS | |||
34.3%negative maspin in squamous cancer | Negative maspin in squamous cell lung cancer = 24% OS 5 years OS | |||
22.8% positive maspin in adenocarcinoma | ||||
59.2% negative maspin |